Published in Science on December 03, 2009
MicroRNAs in stress signaling and human disease. Cell (2012) 6.93
Ischemia and reperfusion--from mechanism to translation. Nat Med (2011) 6.64
Pervasive roles of microRNAs in cardiovascular biology. Nature (2011) 6.08
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
miRNAs in human cancer. J Pathol (2010) 6.02
MicroRNA control of signal transduction. Nat Rev Mol Cell Biol (2010) 5.74
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
The microcosmos of cancer. Nature (2012) 4.50
MicroRNA functions in stress responses. Mol Cell (2010) 4.46
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest (2011) 4.21
Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol (2013) 3.80
MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol (2012) 3.78
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest (2012) 3.46
Viruses, microRNAs, and host interactions. Annu Rev Microbiol (2010) 3.30
MicroRNAs in human cancer. Adv Exp Med Biol (2013) 3.19
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest (2010) 3.04
RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol (2013) 3.00
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov (2012) 2.65
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Rapid electronic detection of probe-specific microRNAs using thin nanopore sensors. Nat Nanotechnol (2010) 2.59
Extracellular microRNA: a new source of biomarkers. Mutat Res (2011) 2.55
Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation (2011) 2.52
Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol (2010) 2.51
Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A (2012) 2.39
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science (2011) 2.36
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell (2013) 2.33
The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest (2011) 2.30
Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology (2010) 2.28
MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology (2012) 2.15
Proinflammatory role for let-7 microRNAS in experimental asthma. J Biol Chem (2010) 2.08
Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A (2011) 2.06
Hepatitis C virus RNA functionally sequesters miR-122. Cell (2015) 2.04
MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol (2013) 2.04
Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res (2011) 2.02
Inhibition of microRNA function by antimiR oligonucleotides. Silence (2012) 2.02
MicroRNAs in neuronal function and dysfunction. Trends Neurosci (2012) 1.94
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol (2013) 1.88
Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol (2010) 1.83
MicroRNAs in lipid metabolism. Curr Opin Lipidol (2011) 1.79
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. Proc Natl Acad Sci U S A (2011) 1.78
Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system. Sci Rep (2014) 1.78
Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol (2013) 1.73
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components. Nucleic Acids Res (2011) 1.67
Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods (2012) 1.67
Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev (2011) 1.66
MicroRNAs shape the neuronal landscape. Neuron (2012) 1.64
Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology (2012) 1.62
MicroRNA therapeutics. Gene Ther (2011) 1.61
Development of microRNA therapeutics is coming of age. EMBO Mol Med (2014) 1.60
MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol (2010) 1.59
Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood (2012) 1.58
Progress in microRNA delivery. J Control Release (2013) 1.58
Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene (2011) 1.56
MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest (2013) 1.55
MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol (2011) 1.54
Recombinant adeno-associated virus-mediated inhibition of microRNA-21 protects mice against the lethal schistosome infection by repressing both IL-13 and transforming growth factor beta 1 pathways. Hepatology (2015) 1.53
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
Developing therapeutic microRNAs for cancer. Gene Ther (2011) 1.49
MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest (2013) 1.49
microRNAs and cholesterol metabolism. Trends Endocrinol Metab (2010) 1.49
Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus influenzae (NTHi) from infected lung. PLoS Pathog (2015) 1.48
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int (2010) 1.48
Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum (2011) 1.46
Nanoparticle-based artificial RNA silencing machinery for antiviral therapy. Proc Natl Acad Sci U S A (2012) 1.45
Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol (2011) 1.45
DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation. J Virol (2010) 1.45
Liver-specific microRNA-122: Biogenesis and function. RNA Biol (2012) 1.45
The role of microRNAs in colorectal cancer. Cancer J (2012) 1.44
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem (2013) 1.43
Human Ago2 is required for efficient microRNA 122 regulation of hepatitis C virus RNA accumulation and translation. J Virol (2010) 1.42
A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J (2011) 1.42
Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res (2010) 1.41
HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol (2011) 1.37
Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol (2012) 1.36
Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A (2011) 1.36
25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol (2013) 1.35
The role of microRNAs in human liver cancers. Semin Oncol (2011) 1.34
MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol (2013) 1.33
MicroRNAs: molecular features and role in cancer. Front Biosci (Landmark Ed) (2012) 1.32
The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr (2011) 1.30
Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res (2011) 1.30
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Antisense reduction of tau in adult mice protects against seizures. J Neurosci (2013) 1.29
Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res (2013) 1.28
Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. Proc Natl Acad Sci U S A (2013) 1.28
MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med (2011) 1.28
Discovering the first microRNA-targeted drug. J Cell Biol (2012) 1.26
Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PLoS One (2011) 1.25
miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Antiviral Res (2010) 1.25
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A (2008) 8.56
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature (2005) 6.21
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology (2005) 5.33
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology (2007) 3.87
Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe (2008) 3.73
Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med (2009) 3.72
Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol (2004) 3.43
Unscrambling hepatitis C virus-host interactions. Nature (2005) 2.83
Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology (2006) 2.69
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology (2007) 1.84
Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother (2007) 1.58
MicroRNA expression in zebrafish embryonic development. Science (2005) 15.52
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46
In situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes. Nat Methods (2006) 6.67
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res (2007) 5.67
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res (2007) 5.25
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A (2008) 5.24
RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA (2005) 4.91
Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet (2011) 4.81
Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res (2008) 4.20
Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res (2004) 3.97
LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene (2006) 3.49
A functional screen implicates microRNA-138-dependent regulation of the depalmitoylation enzyme APT1 in dendritic spine morphogenesis. Nat Cell Biol (2009) 3.44
MicroRNA expression in the adult mouse central nervous system. RNA (2008) 3.12
Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest (2010) 3.04
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat Protoc (2007) 2.80
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res (2009) 2.80
miR-200b mediates post-transcriptional repression of ZFHX1B. RNA (2007) 2.67
The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest (2011) 2.30
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. Proc Natl Acad Sci U S A (2011) 2.05
Inhibition of microRNA function by antimiR oligonucleotides. Silence (2012) 2.02
Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol (2005) 2.02
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A (2009) 2.00
Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun (2002) 1.93
Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One (2007) 1.85
The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol (2008) 1.84
Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res (2009) 1.72
Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A (2012) 1.72
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res (2010) 1.67
OligoDesign: Optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling. Nucleic Acids Res (2003) 1.59
A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther (2008) 1.49
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res (2010) 1.44
Spatio-temporal accumulation of microRNAs is highly coordinated in developing plant tissues. Plant J (2006) 1.44
Pep-13, a plant defense-inducing pathogen-associated pattern from Phytophthora transglutaminases. EMBO J (2002) 1.44
Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther (2006) 1.42
LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood (2012) 1.42
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol (2007) 1.38
Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med (2011) 1.38
Regulation of acute graft-versus-host disease by microRNA-155. Blood (2012) 1.35
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol (2010) 1.32
Coexpression network analysis in abdominal and gluteal adipose tissue reveals regulatory genetic loci for metabolic syndrome and related phenotypes. PLoS Genet (2012) 1.31
Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140. RNA (2008) 1.29
MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res (2009) 1.29
Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res (2013) 1.28
Discovering the first microRNA-targeted drug. J Cell Biol (2012) 1.26
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther (2011) 1.23
Artifactual insulin release from differentiated embryonic stem cells. Diabetes (2004) 1.22
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
miRMaid: a unified programming interface for microRNA data resources. BMC Bioinformatics (2010) 1.20
MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res (2012) 1.19
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One (2010) 1.19
The therapeutic potential of microRNAs in cancer. Cancer J (2012) 1.18
microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci Rep (2013) 1.18
microRNAs in CNS disorders. Neuromolecular Med (2009) 1.17
Mechanisms in endocrinology: micro-RNAs: targets for enhancing osteoblast differentiation and bone formation. Eur J Endocrinol (2011) 1.16
An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther (2008) 1.15
A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther (2012) 1.12
Recombinant Adeno-Associated Virus-Mediated microRNA Delivery into the Postnatal Mouse Brain Reveals a Role for miR-134 in Dendritogenesis in Vivo. Front Neural Circuits (2010) 1.12
Identification and analysis of miRNAs in human breast cancer and teratoma samples using deep sequencing. BMC Med Genomics (2009) 1.10
Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. Nucleic Acids Res (2003) 1.10
LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E. Nucleic Acids Res (2002) 1.09
Targeting of microRNAs for therapeutics. Biochem Soc Trans (2008) 1.03
MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther (2008) 1.03
Reactivation of tuberculosis during immunosuppressive treatment in a patient with a positive QuantiFERON-RD1 test. Scand J Infect Dis (2004) 1.02
High blood pressure despite treatment: results from a cross-sectional primary healthcare-based study in southern Sweden. Scand J Prim Health Care (2006) 1.01
Direct isolation of poly(A)+ RNA from 4 M guanidine thiocyanate-lysed cell extracts using locked nucleic acid-oligo(T) capture. Nucleic Acids Res (2004) 0.98
On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem (2005) 0.97
Involvement of microRNAs in lung cancer biology and therapy. Transl Res (2011) 0.96
MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol (2012) 0.96
Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet (2013) 0.93
Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol (2012) 0.92
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther (2013) 0.91
Short strong hydrogen bonds in proteins: a case study of rhamnogalacturonan acetylesterase. Acta Crystallogr D Biol Crystallogr (2008) 0.90